Antonio Iglesias, MD
Neurology · Maywood, ILNPI 1003142704
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Livanova USA, Inc. at 30.9% of the total. Reporting peaked in 2021 at $3,012 and has fallen 73.6% since, to $795 in 2025.
Across 62 payments — averaging $123.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Genentech USA, Inc.$2K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$459
- Neuropace, Inc.$362
- AstraZeneca$360
- plus $1K from 12 others
Across 8 payments — averaging $94,663 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$525K
- E.r. Squibb & Sons, L.L.C.$130K
- Genentech, Inc.$102K
What the payments were for
- Consulting fees$2,67035%
- Travel & lodging$1,07314%
- Food & beverage$3,74949%
- Education$1712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 12 | $2,369 |
| Genentech USA, Inc. | 1 | $1,500 |
| Johnson & Johnson(2 entities) | 2 | $1,119 |
| E.r. Squibb & Sons, L.L.C. | 8 | $459 |
| Neuropace, Inc. | 1 | $362 |
| AstraZeneca | 3 | $360 |
| Bristol Myers Squibb | 19 | $351 |
| Pfizer | 4 | $280 |
| MDD US Operations, LLC | 2 | $194 |
| Biogen | 1 | $150 |
| TG Therapeutics, Inc. | 2 | $141 |
| Lilly USA, LLC | 1 | $125 |
| F. Hoffmann-la Roche AG | 1 | $80 |
| Novartis | 1 | $78 |
| EMD Serono, Inc. | 1 | $41 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$2,141
- OCREVUS$1,500
- Enspryng$1,500
- RNS Neurostimulator Kit$362
- SOLIRIS$250
- ZEPOSIA$236
- TYSABRI$150
- KISUNLA$125
- BRIUMVI$108
How this compares
$7,663 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 14 | $180,479 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 39 | $133,765 |
| MayzentSiponimod | 12 | $114,190 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $106,709 |
| VumerityDiroximel Fumarate | 12 | $103,600 |
| XcopriCenobamate | 64 | $102,719 |
| TecfideraDimethyl Fumarate | 11 | $97,006 |
| BriviactBrivaracetam | 38 | $62,129 |
| EpidiolexCannabidiol (Cbd) | 16 | $43,407 |
| Lacosamide | 156 | $32,033 |
| InbrijaLevodopa | 18 | $22,147 |
| NayzilamMidazolam | 20 | $21,206 |
| NeuproRotigotine | 18 | $14,955 |
| Levetiracetam | 344 | $12,448 |
| Tiagabine Hcl | 24 | $9,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera | $150 | $200,60623 claims |
| NovartisMayzent | $78 | $114,19012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.
Other neurology in Maywood
- Tyler KaplanMaywood$549K
- Rima DaferMaywood$103K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.